Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04058795 · ClinicalTrials.gov registry record · NA
PTSD Mobile App for Cancer Survivors
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 524
- Enrollment target
NCT04058795: Completed NA study, sponsored by Duke University.
NCT04058795 is a NA study that has completed, run by Duke University. The registered enrollment target is 524 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04058795, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 524 participants
- Enrollment target
Study Summary
The purpose of this study is to use a stepped-care approach in treating symptoms of posttraumatic stress disorder (PTSD). The information learned by doing this study may help us to develop some target treatments for PTSD symptoms in survivors of stem cell transplant. Participants in this study will be randomized to a mobile app or usual care. An assessment will be made after 4 weeks and a determination made of adding more intensive treatment. Participants will be asked to complete a questionnaire 4 times over a period of 6 months, at the time your participation is complete.
Primary Outcome
PCL5 is 20 item instrument scored 0-4, with 0 being "Not at all" and 4 being "Extremely"
Interventions
- BEHAVIORAL Cancer Distress Coach (CaDC) App
- BEHAVIORAL CaDC + mCoaching
- BEHAVIORAL mCBT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2021-01-24 |
| Est. Completion | 2025-05-29 |
| Phase | NA |
What the finished NCT04058795 record still lists
NCT04058795 is an interventional study that assigns participants to a tested intervention. The registered 524 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 3 interventions - of which Cancer Distress Coach (CaDC) App is the first listed.
NCT04058795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04058795 about?
NCT04058795 is a clinical study titled "PTSD Mobile App for Cancer Survivors". The purpose of this study is to use a stepped-care approach in treating symptoms of posttraumatic stress disorder (PTSD). The information learned by doing this study may help us to develop some target treatments for PTSD symptoms in survivors of stem cell transplant. Participants in this study will...
What is the current status of trial NCT04058795?
This trial is currently completed. It is a NA study. The enrollment target is 524 participants. The study started on 2021-01-24. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT04058795?
The interventions under investigation include: Cancer Distress Coach (CaDC) App (BEHAVIORAL), CaDC + mCoaching (BEHAVIORAL), mCBT (BEHAVIORAL).
Who is sponsoring clinical trial NCT04058795?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04058795's enrollment target sits among peer trials
524 189th of 2000 higher than 1,812 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI